News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
He holds a Master’s in Management from the National University of Singapore
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated
